Psychiatr. pro Praxi, 2005; 5: 246-251

Tardivní dyskineze vyvolaná atypickými antipsychotiky u rizikových skupin pacientů

MUDr. Klára Látalová
Psychiatrická klinika FN a LF UP, Olomouc

Tardivní dyskineze (TD) je chronický, polékově navozený extrapyramidový příznak, který pacienta nepříznivě ovlivňuje psychicky a fyzicky a může vést ke ztrátě compliance. Antipsychotika představují nejúčinnější farmaka při léčbě psychotických onemocnění. Antipsychotika první generace (A1G) i antipsychotika druhé generace (A2G) způsobují up-regulaci dopaminových receptorů, proto mohou být zdrojem nežádoucí extrapyramidové symptomatologie (EPS). Na základě prospektivního sledování souboru pacientů jsou stanovena a srovnána rizika TD při léčbě A1G a A2G. Předpokladem je skutečnost, že A1G i A2G mohou způsobovat TD, ale při léčbě A2G je toto riziko signifikantně nižší. Sledovaný soubor je tvořen 98 pacienty a jeho cílem je potvrdit či zpochybnit míru rizika vzniku TD při léčbě A2G.

Published: February 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Látalová K. Tardivní dyskineze vyvolaná atypickými antipsychotiky u rizikových skupin pacientů. Psychiatr. praxi. 2005;9(5):246-251.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Basile VS, Masellis M, Badri F, Paterson AD, Meltzer HY, Lieberman JA, Potkin SG, Macciardi F, Kennedy JL. Association of the MscI polymorphism of the dopamine D3-receptor gene with tardive dyskinesia in schizophrenia, Neuropsychopharmacology 1999; 21: 17-27. Go to original source... Go to PubMed...
    2. Bell RCH, Smith RC. Tardive dyskinesia: characterisation and prevalence in a stadewide system. J Clin Psychiatry 1998; 39: 39-47.
    3. Bergen J, Kitchin R, Berry C. Predictors of course tardive dyskinesia in patients receiving neuroleptics. Biol Psychiatry 1992; 32: 580-594. Go to original source... Go to PubMed...
    4. Bleuler, E. Dementia praecox or the Group of Schizophrenia, New York, Ny: International Universities Press; 1950.
    5. Casey, DE. Tardive dyskinesia: animal models. Psychopharmalogical Bulletin 1984; 20: 376-379.
    6. Casey, DE. Spontaneous and tardive dyskinesia: Clinical and laboratory studies. Journal of Clinical Psychiatry 1985; 46-47. Go to PubMed...
    7. Češková E, Švestka J, Peška I, Náhunek K, Ryšánek R. Pozdni dyskineze při dlouhodobé léčbě neuroleptiky - souhrn literatury a vlastní zkušenosti s jejich léčbou. Cs psychiatrie 1990; 86: 269-274.
    8. Dose M. Recognition and management of acute neuroleptic-induced extrapyramidal motor and mental syndromes. Pharmacopsychiatry 2000; 33 (Suppl 1):3-13. Go to original source... Go to PubMed...
    9. Faurbye A., Rash P. J., Peterson P.B., Brandborg G. & Pekkenberg, G. Neurological symptoms in pharmacotherapy of psychoses. Acta Psychiatrica Scandinavica 1964; 40: 10-27. Go to original source... Go to PubMed...
    10. Fenton WS, Wyatt RJ, Mc Glashan TH. Risk factors for spontaneous dyskinesia in schizophrenia. Arch Gen Psych 1994; 51: 483-486. Go to original source... Go to PubMed...
    11. Fish F. Leonards Classification of Schizophrenia. J Ment Sci 1958; 104: 943-947. Go to original source... Go to PubMed...
    12. Fukuzako H, Tominaga H, Izumi K, Koja T, Nomoto M, Hokazomo Y, Kamei K, Fujii H, Fukuda T, Matsumuto K. Postural myoclonus associated with long-term administration of neuroleptics in schizophrenic patients. Biol Psychiatry 1990; 27: 1116-1126. Go to original source... Go to PubMed...
    13. Gardos G, Casey DE, Cole JO, Perényi A, Kocsis E, Arato M, Samson JA, Conley C. ten-year outcome of tardive dyskinesia. AM J Psychiatry 1994; 151: 836-841. Go to original source... Go to PubMed...
    14. Glazer WM. Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry 2000; 6(Suppl 4): 21-26.
    15. Gune LM, Andersson U, Bondenson U et al. Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration. Pharmacol Biochem Behav 1986; 25: 897-901. Go to original source... Go to PubMed...
    16. Gunne LM, Barany, S. Haloperidol-induced tardive dyskinesia in monkeys. Psychophartmacolgy (Berl) 1976; 50: 237-240. Go to original source... Go to PubMed...
    17. Horáček J. Novel antipsychotics and extrapyramidal side effects. Theory and Reality. Pharmacopsychiatry, 2000; 33 /Suppl 1): 34-42. Go to original source... Go to PubMed...
    18. Chouinard G, Annable L, Ross-Chouinard A et al. Factors related to tardive dyskinesia, Am J Psychiatry, 1979; 136: 79-82. Go to original source... Go to PubMed...
    19. Chouinard G, Annable L, Ross-Chouinard A. Supersensitivity psychosis and tardive dyskinesia: a survey of schizophrenic outpatients. Psychopharmacol Bull 1986; 22: 891-896. Go to PubMed...
    20. Jeste DV, Caligiuru MP, Paulsen JS at al. Risk of tardive dyskinesia in older patient: a prospective lingitudila study of 266 patients. Arch Gen Psychiatry 1995; 52: 756-765. Go to original source... Go to PubMed...
    21. Jeste DV, Lacro JP, Palmer B et al. Incidence od tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. Am J Psychiatry 1999; 156: 309-311. Go to original source... Go to PubMed...
    22. Kane JM Smith JM. Tardive dyskinesia Prevalence and risk factors. Arch Gen Psychiatry 1982; 39: 473-481. Go to original source... Go to PubMed...
    23. Kane JM, Woerner M, Borenstein M el al. Integrating incidence and prevalence of tardive dyskinesia. Psychofarmacol Bull 1986; 22:54-258.
    24. Kerk PE, McElroy SL, Strakowski SM. Anticonvulsats and antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 1998; 59: (Suppl 6): 74-81.
    25. Kraepelin E. Dementia praecox and Paraphrenia, Edinburg, Scotland: E & S Livingstone, 1919.
    26. Krebs MO, Olie JP. Tardive dystonia induced by risperdion [letter]. Canadian Journal of psychiatry 1999; 44: 507-508. Go to PubMed...
    27. Látalová K, Pidrman V, Bouček J. Tardivní dyskineze - klinický obraz a léčba. Psychiatrie pro praxi 2003; 6: 41-65.
    28. Maršálek M. Tardive drug-induced extrapyramidal syndromes. Pharmacopsychiatry 2000; 33n(Suppl 1): 14-33. Go to original source... Go to PubMed...
    29. Maršálek M, Roth Z. Subtypes of tardive dyskinesia (Abstract). Clin Neuropsychopharmacol 1992; 15 (Suppl1): 268B. Go to original source...
    30. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Arch Gen Psych 1993; 50: 723-733. Go to original source... Go to PubMed...
    31. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psych 1982; 39: 486-487. Go to original source... Go to PubMed...
    32. Schönecker M. Reseach diagnosis for tardive dyskinesia. Archi Genl Psych 1957; 39: 486-487. Go to original source...
    33. Sigwald J, Bouttier D, Raymond C, Piot C. Quatre cas de dyskinesie facio-bucco-lingou- masticatice a evalution prolonge secondaire a un traitment par les neuroleptiques. revue Neurologique (Paris), 1959; 100: 751-755. Go to PubMed...
    34. Simpson GM, Angus JWS A rating scale for extrapyramidal side effects. Acta Psych Scand 1970; (Suppl 212): 11-19. Go to original source... Go to PubMed...
    35. Simpson GM, Jaffe ME. Reduction of tardive dystonia with olanzapin. Am J Psych 2000; 42: 852-900.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.